The Global Health Body Issues Warning Over Acute Lack of Obesity Jabs
Under 10% of patients eligible to benefit from GLP-1 drugs like Wegovy have access to them, states the global health agency as it publishes its first advice on the medications.
Considering in excess of 1,000,000,000 people worldwide now obese, it is advocating for increased and just access to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"The new guidance recognises that excess weight is a long-term condition that can be treated with thorough and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are major obstacles to widespread availability to the treatments that can help people shift considerable body mass, notes the body.
GLP-1 Therapy Supply Crisis
Despite the present most favorable scenario, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The recommendation urges nations and manufacturers to widen access, through strategies including patent sharing.
A patent on a key compound – the core component of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026.
The Way Obesity Injections Function
The injections imitate a body's own hormone to reduce digestion speed, curb appetite and boost the sense of being full so individuals eat less.
Individuals typically start to lose weight in the initial weeks of commencing the weekly injections.
Research indicates people may put most of the weight back on after a year of discontinuing the drug, because their normal food cravings return.
Being above a healthy weight raises your chance for contracting diseases, like diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight impacts people in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
